Recovery test after Q4's 39% profit collapse
With profits down sharply last quarter and FII exiting, PI Industries must prove stabilisation on new product traction and margin recovery in Q2.
The setup: stabilisation or further decline?
PI Industries reported a 39% year-on-year collapse in net profit to ₹200 Cr in Q4 FY26, well below analyst consensus, triggering downgrades across the board. The stock has fallen 57% from all-time highs (₹4,804) and now trades 34% below median analyst targets, raising the stakes for Q2: is this a cyclical trough with recovery underway, or a sign of deeper operational challenges? The September registration of Pioxaniliprole — India's first indigenously discovered insecticide — is a material positive that could reshape long-term growth, but the Street wants proof of margin stabilisation and revenue resilience first.
What to expect in Q2
~₹350–370 Cr
on-plan trajectory; depends on formulations mix, pipeline momentum, and pricing realisations
18–22%
swing factor — Q4 pressure signals input-cost headwinds or volume deleveraging; recovery here defines tone
₹35–45 Cr
watch closely — Q4's ₹200 Cr miss flagged cost pressures; stabilisation vs extension matters
A strong Q2 would show: revenue at or above ₹360 Cr, EBITDA margin recovering to 21%+, net profit ₹40+ Cr, and management commentary confirming early Pioxaniliprole traction. A weak Q2 would signal: revenue below ₹350 Cr, margin further compressed, profit below ₹35 Cr, and no visibility on new-product monetization — extending the downtrend and validating recent FII outflow.
On track with guidance?
Unconfirmed. Management's prior FY27 guidance has not been formally reset post-Q4 decline, though the scale of the miss suggests downside revisions are likely. Q1 FY27 results (announced Aug 11) will set a run-rate baseline, but the Q4 miss raises questions about full-year assumptions. The Pioxaniliprole registration in September is strategically significant — it positions PI as an agrochem innovator in addition to a formulator — but ramp timing and contribution in FY27 remain unclear. Management must articulate: (1) whether Q4 was cyclical or structural, (2) FY27 full-year revenue/margin targets, and (3) Pioxaniliprole ramp schedule and market opportunity.
What the Street says
Since Q1 FY27 — recent filings & events
Sep 21
Pioxaniliprole registration approved (insecticide, indigenously discovered)
Material positive — opens new revenue stream; validates R&D capability
Oct 19
PI Foundation incorporation (wholly owned subsidiary, Udaipur)
Likely CSR/strategic entity; routine filing; no operational impact flagged
Oct 27
Board meeting announcement for Nov 4 result approval
On schedule; trading window closed Sep 25 (routine); no insider activity flagged
Ownership trends: FII stake fell from 16.97% (Q1 FY26) to 14.83% (Q1 FY27) — a 204 bps outflow on Q4's profit miss and near-term weakness. DII holdings stable at 31.64%. Promoter unchanged at 46.09%. The FII exit underscores caution on near-term earnings recovery.
Key watch items for result day (Nov 4)
1 · Revenue & margin stabilisation
Does Q2 show revenue back on trajectory (₹360+ Cr) and EBITDA margin recovery (21%+)? A miss here (₹350 Cr or <18% margin) extends the downtrend and validates FII skepticism. A beat resets sentiment toward the ₹3,020 target.
2 · Pioxaniliprole early traction & ramp visibility
What are initial sales, market uptake, and full-year contribution expectations? Management's confidence in monetization timeline (Q2, Q3, or delayed?) will drive the long-term narrative. Lack of detail keeps consensus cautious.
3 · FY27 full-year guidance reset
Will management reaffirm pre-Q4 targets or revise lower? A reset lower validates near-term caution but may unlock upside to FY28 growth. Flat or bullish guidance would support the ₹3,020 consensus; a downside revision extends the HOLD rating.
PI Industries enters Q2 in the doghouse: Q4's 39% profit collapse, FII selling, and a 57% peak-to-trough decline have created a wide credibility gap between the Street's ₹3,020 median target and the stock's ₹2,055 reality. The Pioxaniliprole registration is genuine innovation upside, but it's also a longer-term story — the immediate test is whether the company can stabilise margins, defend revenue, and prove that Q4 was cyclical, not structural. Nov 4 will tell whether this is the inflection point or if further pain awaits.
Informational and educational content only. Not investment advice.